Contribution of 18 Fluorodeoxyglucose positron emission tomography uptake and TTF-1 expression in the evaluation of the EGFR mutation in patients with lung adenocarcinoma

Kanmaz Z. D., Aras G., Tuncay E., Bahadir A., Kocaturk C., Yasar Z. A., ...Daha Fazla

Cancer Biomarkers, cilt.16, sa.3, ss.489-498, 2016 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 16 Sayı: 3
  • Basım Tarihi: 2016
  • Doi Numarası: 10.3233/cbm-160588
  • Dergi Adı: Cancer Biomarkers
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.489-498
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

© 2016 - IOS Press and the authors.AIM: The aim of this study is to evaluate the diagnostic value of PET-CT scan for the prediction of EGFR mutation status and the contribution of TTF-1 expression to PET-CT scan. METHODS: We retrospectively studied 218 cases with a diagnosis of pulmonary adenocarcinoma between 2012-2014 which underwent EGFR analysis, TTF-1 and PET-CT before treatment. RESULTS: The EGFR mutation was present in 28.9% (n = 63) of cases. TTF-1 positivity was 66.9% (n = 105). Standardized uptake value (SUV max) was 16.7 ' 6.8 in EGFR mutant type, 13.8 ' 7.6 in cases having no EGFR mutations. According to our evaluations, high SUVmax is positively correlated with EGFR mutation status. TTF-1 expression in multivariate analysis strengthens the accuracy of detecting an EGFR mutation. CONCLUSION: PET-CT FDG uptake may, together with TTF-1 expression, help diagnosis in lung adenocarcinoma cases when evaluating for EGFR mutation status.